Drug ID:Drug33
Drug Name:Ondansetron
CID:4595
DrugBank ID:DB00904
Modality:Small Molecule
Groups:approved
US Approved:YES
Other Approved:YES
Identifier: NCT05439772
Molecular Formula:C18H19N3O
Molecular Weight:293.4 g/mol
Isomeric SMILES:CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C
Synonyms:ondansetron; 99614-02-5; Zofran ODT; Zudan; Zuplenz; 116002-70-1; Ondansetron Injection; GR 38032X; GR 38032; UNII-4AF302ESOS
Phase 0: 9
Phase 1: 82
Phase 2: 91
Phase 3: 84
Phase 4: 109
Description:A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties. [PubChem]

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
dt305 4595 Ondansetron 1636 ACE Rattus norvegicus (Norway rat) 38437957 Ondansetron inhibits the reaction [cisplatin results in increased expression of ACE protein]
dt306 4595 Ondansetron 834 CASP1 Rattus norvegicus (Norway rat) 38437957 Ondansetron inhibits the reaction [cisplatin results in increased expression of CASP1 protein]
dt307 4595 Ondansetron 836 CASP3 Homo sapiens (human) 34654991 Paclitaxel inhibits the reaction [ondansetron results in increased expression of CASP3 protein modified form]|ondansetron results in increased expression of CASP3 protein modified form
dt308 4595 Ondansetron 836 CASP3 Rattus norvegicus (Norway rat) 38437957 Ondansetron inhibits the reaction [cisplatin results in increased cleavage of CASP3 protein]
dt309 4595 Ondansetron 847 CAT Mus musculus (house mouse) 31332906 Ondansetron promotes the reaction [diclofenac results in decreased activity of CAT protein]
dt310 4595 Ondansetron 1544 CYP1A2 Homo sapiens (human) 15286053 CYP1A2 protein affects the metabolism of ondansetron
dt311 4595 Ondansetron 1565 CYP2D6 Homo sapiens (human) 15286053 CYP2D6 protein affects the metabolism of ondansetron
dt312 4595 Ondansetron 1565 CYP2D6 Homo sapiens (human) 12464242 CYP2D6 protein results in increased metabolism of ondansetron
dt313 4595 Ondansetron 1576 CYP3A4 Homo sapiens (human) 15286053 CYP3A4 protein affects the metabolism of ondansetron
dt314 4595 Ondansetron 2890 GRIA1 Rattus norvegicus (Norway rat) 16794574 Ondansetron inhibits the reaction [cocaine results in increased phosphorylation of GRIA1 protein]

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
NCT05439772 Examining the Effect of Ondansetron on Bowel Prep Success PHASE4 COMPLETED State University of New York - Downstate Medical Center Abdominal Pain; Inflammatory Bowel Diseases; Eosi… DRUG: Ondansetron Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
No data available

Anti-inflammatory effect of ondansetron through 5-HT3 receptors on TNBS-induced…

PMID: 27350767
Year: 2012
Relationship Type: Treatment Score: 6.1

In fl ammatory bowel disease (IBD) is a chronic in fl ammatory disorder of the intestinal tract whose etiology has not yet been fully elucidated. Ava…

View Details
Short-course ondansetron for the prevention of methotrexate-induced nausea in c…

PMID: 21681112
Year: 2011
Relationship Type: Treatment Score: 6.1

OBJECTIVES: Methotrexate (MTX) is an effective treatment for Crohn disease (CD); however, its application may be limited by the occurrence of nausea.…

View Details